• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Celldex Therapeutics Inc.

    5/12/26 10:18:40 AM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $CLDX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    CELLDEX THERAPEUTICS INC

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)




    15117B202

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    15117B202


    1Names of Reporting Persons

    STATE STREET CORPORATION
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,620,053.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,804,168.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,804,168.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.2 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    CELLDEX THERAPEUTICS INC
    (b)Address of issuer's principal executive offices:

    PERRYVILLE III BUILDING 53 FRONTAGE ROAD, SUITE 220, HAMPTON, NEW JERSEY, 08827
    Item 2. 
    (a)Name of person filing:

    STATE STREET CORPORATION;
    (b)Address or principal business office or, if none, residence:

    ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES
    (c)Citizenship:

    MA
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP Number(s):

    15117B202
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    2804168.00
    (b)Percent of class:

    4.2  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    2,620,053

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    2,804,168

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    NOT APPLICABLE
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    SSGA FUNDS MANAGEMENT, INC. (IA);STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA);STATE STREET GLOBAL ADVISORS LIMITED (IA);STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA);STATE STREET GLOBAL ADVISORS, LTD. (IA);
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    NOT APPLICABLE
    Item 9.Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.


    NOT APPLICABLE

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    STATE STREET CORPORATION
     
    Signature:ELIZABETH SCHAEFER
    Name/Title:SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
    Date:05/12/2026
    Get the next $CLDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLDX

    DatePrice TargetRatingAnalyst
    4/20/2026$45.00Underweight → Overweight
    Barclays
    3/23/2026$44.00Peer Perform → Outperform
    Wolfe Research
    10/21/2025$48.00Outperform
    Mizuho
    10/13/2025$25.00Underweight
    Barclays
    4/28/2025$64.00Buy
    Canaccord Genuity
    3/20/2025$46.00Overweight
    Morgan Stanley
    2/13/2025$44.00Buy
    UBS
    10/7/2024$70.00Buy
    Citigroup
    More analyst ratings

    $CLDX
    SEC Filings

    View All

    Celldex Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Celldex Therapeutics, Inc. (0000744218) (Filer)

    7/15/26 4:07:43 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form S-8 filed by Celldex Therapeutics Inc.

    S-8 - Celldex Therapeutics, Inc. (0000744218) (Filer)

    6/26/26 4:01:33 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Celldex Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Celldex Therapeutics, Inc. (0000744218) (Filer)

    6/26/26 8:43:39 AM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CLDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Celldex Therapeutics upgraded by Barclays with a new price target

    Barclays upgraded Celldex Therapeutics from Underweight to Overweight and set a new price target of $45.00

    4/20/26 8:20:25 AM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Celldex Therapeutics upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Celldex Therapeutics from Peer Perform to Outperform and set a new price target of $44.00

    3/23/26 8:22:59 AM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Mizuho initiated coverage on Celldex Therapeutics with a new price target

    Mizuho initiated coverage of Celldex Therapeutics with a rating of Outperform and set a new price target of $48.00

    10/21/25 7:19:21 AM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CLDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CEO Marucci Anthony S bought $308,430 worth of shares (11,500 units at $26.82), increasing direct ownership by 40% to 40,284 units (SEC Form 4)

    4 - Celldex Therapeutics, Inc. (0000744218) (Issuer)

    11/12/24 8:01:10 AM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CLDX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis

    Study did not meet key efficacy objectives Favorable safety profile consistent with prior studies, including with new 450mg loading dose and up to 300mgQ4W regimenProfound systemic mast cell depletion, as evidenced by significant reduction in serum tryptase, observed Phase 3 CSU topline data expected in Sept/Oct 2026; Phase 3 SD and ColdU Enrollment On Track; Phase 2 topline data in AD in late 2026Company to host webcast today at 4:30 pm ET HAMPTON, N.J., July 21, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported topline results from the Company’s Phase 2 study of barzolvolimab delivered subcutaneously in prurigo nodularis (PN), a chronic skin disease that causes hard, intense

    7/21/26 4:01:00 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Celldex Announces Planned Transition of Chief Financial Officer

    HAMPTON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that Sam Martin, Senior Vice President and Chief Financial Officer, has informed the Company of his plans to retire in 2027. Mr. Martin has served as the Company’s Chief Financial Officer since 2017 and as a member of the Celldex finance team since April 2009. Celldex has initiated a search for a new Chief Financial Officer, and Mr. Martin will remain as the Company’s CFO through March of 2027, to support a smooth transition. "We are grateful to Sam for his strong contributions over many years of service to Celldex and wish him the very best in his retirement," said Anthony Marucci, Co-founder, Presiden

    7/15/26 4:01:00 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

    Treatment with barzolvolimab resulted in rapid, significant, and durable improvements in angioedema in patients with moderate to severe CSUSeven months after the completion of dosing (Week 76), up to 64% of patients treated with barzolvolimab who had angioedema at baseline remained angioedema-free Barzolvolimab has potential to shift treatment goals from symptom control to disease modificationResults continue to support ongoing Phase 3 trials of barzolvolimab in CSU; topline data expected in Q4 2026 HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at

    6/14/26 10:21:00 AM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CLDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by SVP & Chief Commercial Officer Lawver Teri L

    4 - Celldex Therapeutics, Inc. (0000744218) (Issuer)

    6/29/26 4:21:58 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by SVP & GENERAL COUNSEL Jimenez Freddy A.

    4 - Celldex Therapeutics, Inc. (0000744218) (Issuer)

    6/29/26 4:21:16 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by SVP, CHIEF MEDICAL OFFICER Young Diane C.

    4 - Celldex Therapeutics, Inc. (0000744218) (Issuer)

    6/29/26 4:20:30 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CLDX
    Leadership Updates

    Live Leadership Updates

    View All

    Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer

    HAMPTON, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Ms. Lawver is an accomplished global healthcare executive with 30 years of strategic, commercial launch and operating P&L leadership across the biopharmaceutical, medical device and consumer health technology sectors. Ms. Lawver succeeds Richard Wright, who will retire from Celldex following more than a decade of dedicated leadership and service. "We are thrilled to welcome Teri to the Celldex leadership team," said Anthony Marucci, Co-founder, President, and Chief Executive Officer of Celldex. "Teri brings an extraordina

    11/10/25 8:01:00 AM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors

    HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company's Board of Directors. "We are excited to welcome Denice to the Celldex Board of Directors," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex. "Denice's extensive leadership experience across both the pharmaceutical and consumer healthcare sectors brings a deep operational and commercial perspective to our team. Her track record of driving strategic growth and operational excellence will be instrumental as we advance our clinical programs and continue building our organization." Ms. Torres added, "

    6/6/25 8:01:00 AM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

    HAMPTON, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that it has appointed Rita Jain, M.D. to the Company's Board of Directors. "We are pleased to welcome Dr. Jain to the Celldex Board of Directors at this important time in the Company's trajectory," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics. "Dr. Jain's deep background in drug development strongly complements our Board's skills and experiences, and we look forward to her contributions as we continue to advance our programs into later stage development." Dr. Jain added, "I am excited to join Celldex, whose emerging data suggests tha

    2/16/23 4:01:00 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CLDX
    Financials

    Live finance-specific insights

    View All

    Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis

    Study did not meet key efficacy objectives Favorable safety profile consistent with prior studies, including with new 450mg loading dose and up to 300mgQ4W regimenProfound systemic mast cell depletion, as evidenced by significant reduction in serum tryptase, observed Phase 3 CSU topline data expected in Sept/Oct 2026; Phase 3 SD and ColdU Enrollment On Track; Phase 2 topline data in AD in late 2026Company to host webcast today at 4:30 pm ET HAMPTON, N.J., July 21, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported topline results from the Company’s Phase 2 study of barzolvolimab delivered subcutaneously in prurigo nodularis (PN), a chronic skin disease that causes hard, intense

    7/21/26 4:01:00 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)

    Study met primary endpoint demonstrating barzolvolimab's ability to potently deplete mast cells in the gastrointestinal tractProfound mast cell depletion did not result in improved clinical outcomes providing direct evidence that mast cells are not a primary driver in EoE Favorable safety profile demonstrated for barzolvolimab 300 mg Q4 weekly dosing regimenCompany to host webcast today at 4:30 pm ET HAMPTON, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported topline results from the Company's ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus. Identifying the key drivers of

    8/19/25 4:01:00 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

    Seven months after the completion of dosing: 41% of patients (150 mg Q4W) continue to experience complete response (UAS7=0)48% of patients (150 mg Q4W) report that CSU no longer impacts their quality of life (DLQI=0/1)KIT related tolerability events demonstrated to be reversible Enrollment to Phase 3 CSU trials ongoingCompany to host webcast today at 6:00 pm ET HAMPTON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab in chronic spontaneous urticaria (CSU), an immune-related condition driven by mast c

    6/12/25 6:01:00 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CLDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Celldex Therapeutics Inc.

    SC 13G/A - Celldex Therapeutics, Inc. (0000744218) (Subject)

    11/14/24 7:47:25 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Celldex Therapeutics Inc.

    SC 13G/A - Celldex Therapeutics, Inc. (0000744218) (Subject)

    11/14/24 12:18:08 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Celldex Therapeutics Inc.

    SC 13G/A - Celldex Therapeutics, Inc. (0000744218) (Subject)

    11/14/24 6:12:56 AM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care